FDA approves Citius Pharmaceuticals’ Lymphir for the treatment of relapsed or refractory cutaneous T-cell lymphoma

Lymphir is the first therapy targeting the IL-2 receptor for the treatment of relapsed or refractory cutaneous T-cell lymphoma and is Citius Pharmaceuticals’ first FDA-approved product.